Is CJC-1295 Legal in Australia?

The short answer

CJC-1295 is not an approved medicine in Australia. It is not listed on the Australian Register of Therapeutic Goods (ARTG), which means the Therapeutic Goods Administration (TGA) has not assessed or approved it for human therapeutic use. As a synthetic growth hormone releasing hormone (GHRH) analogue, it sits in the broad category of growth hormone secretagogues and releasing factors that Australian regulators treat as prescription-only, unapproved substances rather than freely available products.

In practice this means CJC-1295 is not something a member of the public can lawfully buy for personal human use without appropriate authorisation. It is supplied in Australia strictly as a research compound for laboratory and research use only, not for human consumption. It is also prohibited in sport at all times under anti-doping rules. The sections below explain each of these points in plain terms.

How the TGA and the Poisons Standard treat it

In Australia, medicines and poisons are classified under the Poisons Standard, also known as the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). Scheduling sets the level of control over how a substance can be supplied, from pharmacy and prescription-only categories through to prohibited substances.

CJC-1295 is a synthetic analogue of growth hormone releasing hormone. Peptide hormones and growth hormone secretagogues of this kind are generally captured by prescription-only controls in Australia, meaning they would require a valid prescription and appropriate authorisation to supply for human use. CJC-1295 has previously been the subject of TGA scheduling consideration, and it is consistently handled as an unapproved, prescription-only type substance rather than an over-the-counter or freely traded product.

To avoid overstating the position, we do not quote a specific schedule number or effective date here. The key, well-established point is that CJC-1295 is not approved for general human therapeutic use and is not something the public can lawfully obtain for personal use without proper authorisation. Anyone needing the precise current classification should check the Poisons Standard directly on the Federal Register of Legislation.

Not approved and not on the ARTG

The ARTG is the official register of therapeutic goods that may lawfully be supplied in Australia. If a medicine is not on the ARTG, it has not been evaluated by the TGA for quality, safety and efficacy, and it cannot be marketed or supplied for human therapeutic use in the ordinary way.

CJC-1295 is not on the ARTG. There is no TGA-approved CJC-1295 product for human use in Australia. This is an important distinction. A substance can be widely discussed in research and online yet still carry no regulatory approval. CJC-1295 falls into that group: it is studied as an experimental compound but is not an approved medicine here or, to the best of current public knowledge, in comparable overseas markets for general therapeutic use.

Research compound versus approved medicine

It helps to separate what an approved medicine is from what a research compound is. An approved medicine has been through TGA evaluation, carries an ARTG number, has agreed labelling and quality standards, and may be prescribed or supplied within defined rules. A research compound has none of that regulatory wrapping. It is intended for laboratory investigation, not for human use.

Where CJC-1295 sits

• Not evaluated or approved by the TGA for human therapeutic use
• Not listed on the ARTG and carries no ARTG number
• Has no approved labelling, dosing instructions or therapeutic indications in Australia
• Treated as a prescription-only, unapproved substance rather than a consumer product
• Supplied by research suppliers for laboratory and research use only, not for human consumption

Because CJC-1295 is a research compound rather than an approved medicine, no claims can lawfully or honestly be made about treating, curing or improving any condition in people. Material that presents it as a finished human product is misleading. The accurate framing is simple: it is a substance studied in research settings, not an approved therapeutic good.

What research use only (RUO) means

Research use only, often shortened to RUO, describes a product supplied solely for laboratory or scientific research. It is not intended, labelled or sold for use in or on the human body, and it is not a diagnostic or therapeutic product. RUO framing is the correct and lawful way for a supplier to make an unapproved research compound such as CJC-1295 available in Australia.

When a compound is supplied RUO, the responsibility sits with the purchaser to use it appropriately within a legitimate research context and in line with any applicable laws and institutional requirements. RUO is not a loophole for human use. It is an honest statement that the product has not been approved for people and must not be treated as a medicine. NovaPeptides supplies CJC-1295 on exactly this basis.

What CJC-1295 is and what the science shows

CJC-1295 is a synthetic peptide designed as an analogue of growth hormone releasing hormone (GHRH), the natural signal that prompts the pituitary gland to release growth hormone. Its structure includes amino acid substitutions intended to make it more resistant to rapid breakdown than native GHRH.

It is commonly discussed in two forms. CJC-1295 with DAC uses Drug Affinity Complex technology, a linker designed to bind the peptide to albumin in the blood so that it circulates for far longer, with reported half-lives in the order of several days in early studies. CJC-1295 without DAC lacks this linker and is often sold under the names modified GRF 1-29 or mod GRF 1-29; it has a much shorter reported half-life, on the order of minutes. These are mechanistic descriptions drawn from the research literature, not statements of human benefit.

The human evidence base for CJC-1295 is limited. Published work is largely early-phase or small in scale, with some early clinical studies reporting changes in growth hormone and IGF-1 markers after administration, alongside preclinical research. There are no large, completed efficacy trials establishing it as a treatment, and it is not approved as a medicine. For that reason, any firm claims about outcomes in people would go beyond what the evidence supports.

The honest summary is that CJC-1295 is an experimental GHRH analogue studied in research settings, not a proven or approved therapy.

CJC-1295 and anti-doping rules

CJC-1295 is prohibited in sport. Sport Integrity Australia and the World Anti-Doping Agency (WADA) classify it under section S2 of the Prohibited List, which covers peptide hormones, growth factors, related substances and mimetics, specifically the growth hormone releasing factors and secretagogues. It is listed alongside similar compounds such as CJC-1293, sermorelin and tesamorelin.

Substances in this category are prohibited at all times, meaning both in-competition and out-of-competition. Athletes who are subject to anti-doping rules therefore face sanctions for the presence, use, attempted use or possession of CJC-1295. Australian cases have resulted in multi-year bans involving this class of substance. Anyone bound by anti-doping rules should treat CJC-1295 as strictly off limits.

A note on personal importation

People sometimes ask whether an unapproved substance can simply be imported for personal use. Australia does operate a Personal Importation Scheme, but it has conditions and does not provide a free pass for every substance. Prescription-only and injectable substances in particular carry significant restrictions, and importing an unapproved, prescription-type substance without the required authorisation can breach customs and therapeutic goods rules.

Given that CJC-1295 is unapproved and treated as prescription-only, importing it for personal human use is not a straightforward or low-risk option, and it may be unlawful depending on the circumstances. This article does not provide instructions on importation. If you have a legitimate reason to consider importing any therapeutic substance, confirm the current rules with the TGA and the Australian Border Force first.

How NovaPeptides supplies CJC-1295

NovaPeptides supplies CJC-1295 strictly for research use only. It is not sold for human consumption, diagnosis or treatment, and no therapeutic claims are made about it. This RUO framing reflects the regulatory reality set out above: CJC-1295 is an unapproved research compound, not an approved medicine.

What research buyers can expect

• Supplied for laboratory and research use only, never for human use
• Independently lab-tested, with a Novagen certificate of analysis (COA) available
• Ships within Australia from the Gold Coast
• Enquiries handled via WhatsApp

Independent testing and a documented COA matter because they speak to the identity and quality of what is actually in the vial, which is central to legitimate research. If you have questions about a specific batch, its certificate of analysis or availability, you can reach the NovaPeptides team via WhatsApp.

Frequently asked questions